PHEREXA: A phase III study of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting

Category Primary study
JournalJournal of Clinical Oncology
Year 2016
This article has no abstract
Epistemonikos ID: 4311cc14db104f673269fb49e2c9c09923403036
First added on: Feb 07, 2025